EIC2025
Programme
Main Topics
Iron deficiency in different organs and systems
Intravenous iron: benefits and risks
Mechanisms of iron overload disorders
How best to diagnose and treat haemochromatosis
Interactions of iron metabolism and bone health
The heart, cardiovascular disease and iron
How iron deficiency and iron overload influence haematopoiesis and immunity
| Iron, bone, heart, cancer, infections & Hepcidin | |
|---|---|
| 08.15 – 08.30 | Welcome and Introduction |
| 08.30 – 10.15 | Iron and bone Chair: State of the art: Iron and bone Oral presentations O-01 Osteoclast-Specific Iron Deficiency Promotes Hypoxia-mediated Bone Loss O-02 Eosinophils drive iron-induced aggravation of pathological bone formation O-03 Ferric Carboxymaltose Increases Fracture Risk in Patients and Reduces Bone Formation in Mice with Iron Deficiency Anemia O-04 4-octyl itaconate rescues osteomalacia and FGF-23 levels in FDI-treated mice Poster flash talks P-24 Gastrointestinally Stabilized Thermostable Exoshells for Oral Iron Repletion Therapy P-01 Cellular iron deficiency impairs mast cell development and degranulation P-08 The Good, the Bad and the Ugly: Iron Metabolism, Hypoxia and Cardiolipin in the Context of Tamoxifen Resistance P-05 Bone loss and iron overload: does it matter? |
| 10.15 – 11.00 | Coffee break & poster viewing |
| 11.00 – 11.45 | EIC Bussiness Meeting |
| 11.45 – 13.15 | Iron, immunology and cancer Chair: State of the art: Iron, immunology and cancer Oral presentations O-05 Iron Deprivation Counteracts Systemic Autoimmune Inflammation O-06 The iron chaperone PCBP2 controls iron homeostasis in iron-reycling macrophages O-07 Disrupted iron homeostasis and risk of bacteraemia in Kenyan children with severe anaemia O-08 Anemia in the Elderly and Clonal Hematopoiesis of Indeterminate Potential: Preliminary Results of an Italian Multicenter Study |
| 13.15 – 14.30 | Lunch |
| 14.30 – 16.00 | Bone morphogenic proteins Chair: State of the art: Bone morphogenic proteins Oral presentations O-09 Endothelial Nrf2 is required to co-ordinate production of BMP6 and hepcidin with hepatic iron loading O-10 TFR2 interacts with ALK3/BMP signaling to regulate bone mass O-11 Transferrin receptor 1-mediated iron uptake mediates thermogenesis in human adipocytes Poster flash talks P-09 Biophysical MRI Signal Modeling Reveals Cerebral Iron Clustering in Aceruloplasminemia P-16 Iron-induced hypophosphatemia: from a case-report to a proposal for a management flowchart P-30 IV iron preparations that are often used interchangeably in the clinic cause different phenotypic alterations in macrophages P-21 Hepatic osteodystrophy and sarcopenia: the role of iron metabolism in advanced liver disease P-17 The prognostic value of hyperferritinemia in severe infection and sepsis |
| 16.00 – 16.45 | Coffee break & poster session |
| 16.45 – 18.00 | Cellular iron metabolism Chair: State of the art: From Hepcidin regulation to iron recycling Oral presentations O-12 Cell-type specific iron content regulation revealed by single-cell iron quantification O-13 Ironing Out Blood Transfusion: The Role of Perioperative Iron Infusion in Hepatobiliary Cancer Surgery O-14 Adaptations of Skeletal Muscle to Iron Deficiency Anemia and Recovery after Intravenous Iron Therapy |
| 19.00 | Gala Dinner |
| Brain iron and Hemochromatosis | |
|---|---|
| 08.30 – 10.00 | Hemochromatosis Chair: State of the art: What’s causing Hemochromatosis – low hepcidin, NTBI or tissue iron overload? Oral presentations O-15 Dysregulation of hepcidin in Hemochromatosis: Results from a multinational cross-sectional study on serum iron parameters and MRI O-16 Defining Ferritin Decision Limits: Addressing the Uncertainty O-17 Association of serum ferritin with persistent infarct core iron after ST-elevation myocardial infarction O-18 Impact of Dietary Iron on Cardiac Function and Iron Distribution in Heart Failure |
| 10.00 – 10.15 | Addressing patient needs in hemochromatosis through a novel targeted approach |
| 10.15 – 10.45 | Coffee break & poster viewing |
| 10.45 – 11.45 | Panel discussion – Diagnostic criteria and hepcidin directed therapy for Hemochromatosis Chair: Panel discussion: |
| 11.45 – 13.15 | Brain iron Chair: State of the art: Brain iron Towards a ceruloplasmin protein replacement therapy in aceruloplasminemia Oral presentations O-20 Long-term sequential iron chelation with Deferasirox and Deferiprone in Aceruloplasminemia: a case series of two brothers with sustained neurological improvement O-21 Quantitative Post Mortem MRI Reveals Sex-Dependent Patterns of Brain Iron in Alzheimer’s Disease Role of myeloperoxidase-mediated neuroinflammation in Aceruloplasminemia |
| 13.15 – 13.45 | Lunch |
| 13.45 – 14.30 | Panel discussion – IV iron in heart failure – Hope or dope Panel discussion: |
| 14.30 – 16.00 | Iron overload Chair: State of the art: What has UK biobank taught us about Hemochromatosis? Oral presentations O-23 Haemochromatosis and the Bone Density Paradox: Elevated Fracture Risk in Male C282Y Homozygotes O-24 Prevalence of intolerance, insufficient response to phlebotomy, and treatment-related burden among adults with hereditary hemochromatosis in the United States O-26 Modeling Iron Deficiency and Overload in Human iPSC-Derived Cardiomyocytes O-30 Impact of Long-Term Venesection on Myocardial Mechanics in HFE-Related Hereditary Hemochromatosis |
| 16.00 – 16.45 | Coffee break & poster session |
| 16.45 – 18.00 | Systemic iron metabolism Chair: State of the art: Labile iron from Loch Ness monster to ferroptosis demon Oral presentations O-27 Ceruloplasmin is required for hepatocellular – but not macrophage-iron export O-28 Hepcidin dynamics predict outcomes in COVID-19 patients treated with interleukin inhibitors O-29 Iron excess alters in vitro deposition of collagen and hydroxyapatite by osteogenic cells |
